Are statins effective in preventing chronic rhinosinusitis? A systematic review and meta‐analysis

Abstract

AbstractObjectivesTo evaluate the association between statin use and chronic rhinosinusitis (CRS).Design and SettingSystematic review and meta‐analysis. The methodological quality of studies was assessed using the Newcastle–Ottawa scale.ParticipantsPatients with CRS.Main Outcome MeasuresPooled odds ratios (ORs) with 95% confidence interval (CIs) in analyses of studies that compared the prevalence of CRS, nasal polyp, difference of Lund‐Kennedy endoscopic score, Lund‐Mackay CT score and Sino‐nasal Outcome Test‐22.ResultsThe analysis included eight studies and 445 465 patients. Patients who used statins were at lower risk for CRS than those who did not (OR = 0.7457, 95% CI = 0.6629–0.8388, p < 0.0001, I2 = 0.0%). Patients with hyperlipidaemia were at higher risk for CRS than those with normal serum levels of lipid (OR = 1.3590, 95% CI = 1.2831–1.4394, p < 0.0001, I2 = 33.3%). However, there were no significant differences in the risk for nasal polyps between CRS patients using statins or not (OR = 1.0931, 95% CI = 0.7860–1.5202, p = 0.5968, I2 = 0.0%). Additionally, statin use was not related to Lund‐Kennedy endoscopic scores, Lund‐Mackay CT scores or sino‐nasal outcome test‐22 scores in CRS patients.ConclusionThe risk for CRS is lower in patients who use statins and those without hyperlipidaemia.